Aptevo Therapeutics Inc. - Common Stock, $0.001 par value per share (APVO)
CUSIP: 03835L702
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock, $0.001 par value per share
- Shares outstanding
- 1,022,610
- Total 13F shares
- 20,293
- Share change
- +20,293
- Total reported value
- $191,356
- Price per share
- $9.43
- Number of holders
- 10
- Value change
- +$191,356
- Number of buys
- 10
Quarterly Holders Quick Answers
What is CUSIP 03835L702?
CUSIP 03835L702 identifies APVO - Aptevo Therapeutics Inc. - Common Stock, $0.001 par value per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
- Newer quarter: Q1 2026
Recent filing periods for CUSIP 03835L702:
Top shareholders of APVO - Aptevo Therapeutics Inc. - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| YA II PN, Ltd. |
13D/G
|
— |
10%
|
357,842
|
$1,663,965 | $0 | 16 Jun 2025 | |
| CVI Investments, Inc. |
13D/G
|
— |
8.2%
|
83,854
|
$744,624 | $0 | 31 Dec 2025 | |
| L1 Capital Global Opportunities Master Fund, Ltd. |
13D/G
|
— |
5%
|
164,300
|
$492,900 | -$362,100 | 14 Aug 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
9.1%
|
299,944
|
$434,919 | — | 30 Sep 2025 | |
| DRW Securities, LLC |
13F
|
Company |
4%
|
131,480
|
$190,646 | — | 30 Sep 2025 | |
| Ayrton Capital LLC |
13D/G
|
— |
10%
|
358,150
|
$107,445 | $0 | 30 Jun 2025 | |
| Virtu Financial LLC |
13F
|
Company |
1.2%
|
38,282
|
$56,000 | — | 30 Sep 2025 | |
| Hudson Bay Capital Management LP |
13D/G
|
— |
5%
|
76,598
|
$52,853 | $0 | 31 Dec 2024 | |
| Grady Grant III |
3/4/5
|
Director |
—
mixed-class rows
|
20,714
mixed-class rows
|
$20,135 | +$20,134 | 10 Nov 2025 | |
| Focus Partners Wealth |
13F
|
Company |
0.3%
|
10,000
|
$14,500 | — | 30 Sep 2025 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0.2%
|
6,500
|
$9,760 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
0.17%
|
5,673
|
$8,226 | — | 30 Sep 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.04%
|
1,445
|
$2,095 | — | 30 Sep 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0.02%
|
570
|
$827 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13D/G
3/4/5
13F
|
10%+ Owner · Company |
0%
|
86
|
$125 | -$715,879 | 31 Oct 2025 | |
| CITIGROUP INC |
13F
|
Company |
0%
|
74
|
$107 | — | 30 Sep 2025 | |
| Marvin L. White |
3/4/5
|
President and CEO, Director |
—
mixed-class rows
|
30,012
mixed-class rows
|
$3 | — | 06 Aug 2025 | |
| Jeffrey G. Lamothe |
3/4/5
|
EVP, COO |
—
mixed-class rows
|
17,306
mixed-class rows
|
$1 | — | 06 Aug 2025 | |
| SoYoung Kwon |
3/4/5
|
SVP, GC, BD & Corp Affairs |
—
mixed-class rows
|
11,504
mixed-class rows
|
$1 | — | 06 Aug 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0%
|
1
|
$1 | — | 30 Sep 2025 | |
| DANSKE BANK A/S |
13F
|
Company |
0%
|
1
|
$1 | — | 30 Sep 2025 | |
| BIGGER CAPITAL FUND L P |
13D/G
|
— |
10%
|
285,000
|
— | $0 | 18 Jun 2025 | |
| Fuad El-Hibri |
3/4/5
|
Director |
—
class O/S missing
|
87,697
|
— | — | 03 Dec 2021 | |
| Daphne Taylor |
3/4/5
|
SVP, CFO |
—
mixed-class rows
|
11,503
mixed-class rows
|
— | — | 06 Aug 2025 | |
| Dirk Huebner |
3/4/5
|
SVP, CMO |
—
class O/S missing
|
11,500
|
— | — | 06 Aug 2025 | |
| Barbara Lopez Kunz |
3/4/5
|
Director |
—
mixed-class rows
|
7,201
mixed-class rows
|
— | — | 06 Aug 2025 | |
| Daniel Abdun-Nabi |
3/4/5
|
Director |
—
mixed-class rows
|
7,201
mixed-class rows
|
— | — | 06 Aug 2025 | |
| John Niederhuber |
3/4/5
|
Director |
—
mixed-class rows
|
7,201
mixed-class rows
|
— | — | 06 Aug 2025 | |
| Zsolt Harsanyi |
3/4/5
|
Director |
—
mixed-class rows
|
7,201
mixed-class rows
|
— | — | 06 Aug 2025 |
Institutional Holders of Aptevo Therapeutics Inc. - Common Stock, $0.001 par value per share (APVO) as of Q4 2025
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q4 2025 Across Filers
| Investor | Q4 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
An asterisk sign (*) next to the price indicates that the price is likely invalid.